Recurrent Melanoma Completed Phase 2 Trials for Dasatinib (DB01254)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00436605Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV MelanomaTreatment